Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Clinical Investigation|February 13, 2024
PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in miceElselien Frijlink, Douwe M T Bosma, Julia Busselaar, et al.
Mbio|December 26, 2019
Long-Term Effects of Early-Life Antibiotic Exposure on Resistance to Subsequent Bacterial InfectionClaire Roubaud-Baudron, Victoria E Ruiz, Alexander M Swan, et al.
Elife|March 26, 2021
Microbial genetic and transcriptional contributions to oxalate degradation by the gut microbiota in health and diseaseMenghan Liu, Joseph C Devlin, Jiyuan Hu, et al.
Cell Reports. Medicine|January 21, 2026
CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistanceAlex Watterson, Gabriele Picco, Vivien Veninga, et al.
Cell|April 10, 2024
A pan-cancer analysis of the microbiome in metastatic cancerThomas W Battaglia, Iris L Mimpen, Joleen J H Traets, et al.
The Journal of Pathology|May 15, 2024
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapyBirgit S Geurts, Laurien J Zeverijn, Jade M van Berge Henegouwen, et al.
Nature|January 11, 2023
γδ T cells are effectors of immunotherapy in cancers with HLA class I defectsNatasja L de Vries, Joris van de Haar, Vivien Veninga, et al.
Cancer Discovery|September 25, 2025
Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade TherapyIris L Mimpen, Thomas W Battaglia, Miguel Parra-Martinez, et al.
BMC Cancer|March 4, 2023
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumoursBirgit S Geurts, Thomas W Battaglia, J Maxime van Berge Henegouwen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2024
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery ProtocolLaurien J Zeverijn, Birgit S Geurts, Thomas W Battaglia, et al.
Pageof 1